Bacteriophages as potential new therapeutics to replace or supplement antibiotics

Trends in Biotechnology

Volumn 28, Issue 12, 2010, Pages 591-595

  Kutateladze, Mzia ^a   Adamia, Revaz ^a  

^a George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE THERAPY; BACTERIAL DISEASE; BACTERIAL INFECTIONS; BACTERIAL PATHOGENS; DRUG-RESISTANT BACTERIA; PHAGE THERAPY;

ANTIBIOTICS; BACTERIOLOGY; DISEASE CONTROL; DRUG THERAPY;

BACTERIOPHAGES;

ANTIBIOTIC AGENT; BACTERIUM LYSATE; METICILLIN; PENICILLIN G; PROBIOTIC AGENT; STAPHYLOCOCCAL PHAGE LYSATE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIOPHAGE; BRONCHIECTASIS; BRONCHITIS; BURN INFECTION; CHRONIC LUNG ABSCESS; DIARRHEA; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DYSENTERY; HOSPITAL PATIENT; HUMAN; INFLAMMATION; INTESTINE INFECTION; LUNG CYST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATHOGENESIS; PENICILLIN RESISTANCE; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; SCIENTIST; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS PHAGE; TYPHOID FEVER; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; COMPLEMENTARY THERAPIES; DRUG RESISTANCE, BACTERIAL; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 78149468115     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.08.001     Document Type: Article

References (38)

1. d'Herelle F. Sur un microbe invisible antagoniste des bacteries dysenteriques. C. R. Acad. Sci. 1917, 165:373-375.
2. Straub M.E., Appelbaum M. Studies of commercial bacteriophage products. J. Am. Med. Assoc. 1932, 100:110-113. Physicians' information booklets published by Parke, Davis and Squibb Cited by T. Hausler (2006).
3. Straub M.E., Rakieten M.L. Studies with Staphylococcus bacteriophage I. The preparation of polyvalent Staphylococcus bacteriophage. Yale J. Biol. Med. 1932, 4:807-819. Cited by T. Hausler (2006).
4. Gratia A. Essais de therapeutique au moyen du bacteriophage du staphylocoque. C. R. Soc. Biol. 1922, 86:276-278. Cited by T. Hausler (2006).
5. Pockels W. Die Bakteriophagentherapie in der Kinderheilkunde. Monatsschir. Kinderheilkunde 1927, 35:229-236. Cited by T. Hausler (2006).
6. Overview of Healthcare-associated MRSA 2008, Centers for Disease Control, Prevention, U.S. Department of Health and Human Services.
7. Goldstein F.W. Penicillin-resistant Streptococcus pneumoniae: selection by both β-lactam and non-β-lactam antibiotics. J. Antimicrob. Chemother. 1999, 44:141-144.
8. Shetty N., Wilson A.P.R. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2000, 46:633-638.
9. Byers K.E., et al. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect. Control. Hosp. Epidemiol. 2001, 22:140-147.
10. Gold H.S. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin. Infect Dis. 2001, 33:210-219.
11. Lepage Ph., et al. Severe multiresistant Salmonella typhimurium systemic infections in Central Africa - clinical features and treatment in a paediatric department. J. Antimicrob. Chemother. 1984, 14:153-159.
12. Escribano I., et al. Relation between induction of the mar operon and cyclohexane tolerance and reduction in fluoroquinolone susceptibility in Salmonella spp. J. Infect. Chemother. 2006, 12:177-180.
13. Cebrian L., et al. Effect of exposure to fluoroquinolones and beta-lactams on the in vitro activity of other groups of antibiotics in Salmonella spp. APMIS 2006, 114:523-528.
14. Amarala L., et al. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 2001, 47:505-511.
15. Amaral L., et al. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 1996, 38:1049-1053.
16. Data from the American College of Physicians.
17. Gill J., Hayman P. Phage choice, isolation and preparation for phage therapy. Curr. Pharm. Biotechnol. 2010, 11:2-14.
18. Goodridge L. Designing phage therapeutics. Curr. Pharm. Biotechnol. 2010, 11:15-27.
19. Merril C., et al. Phage therapy. The Bacteriophages 2006, 725-741. Oxford University Press. R. Calendar (Ed.).
20. Hausler T. Viruses vs Superbugs. A Solution to the Antibiotic Crisis? 2006, Macmillan.
21. Salmon G.G., Symonds M. Staphage lysate therapy in chronic staphylococcal infections. J. Med. Soc. N. J. 1963, 60:188-193.
22. Chanishvili, N. (2009) A Literature Review of the Practical Application of Bacteriophages Research. Eliava Institute of Bacteriophages, Microbiology and Virology.
23. Chanishvili N., et al. Phages and their application against drug-resistant bacteria. J. Chem. Technol. Biotechnol. 2001, 76:689-699.
24. Chanishvili N., Sharp R. Bacteriophage therapy: experience from the Eliava Institute, Georgia. Aust. Microbiol. 2008, 20:96-101.
25. Kutateladze M., Adamia R. Phage therapy experience at the Eliava Institute. Med. Malad. Infect. 2008, 38:426-430.
26. Kutter E., Sulakvelidze A. Bacteriophages: Biology and Applications 2005, CRC Press.
27. Sulakvelidze A., et al. Bacteriophage therapy, minireview. Antimicrob. Agents Chemother. 2001, 45:649-659.
28. Isashvili, N.P. (1957) Combined use of penicillin and bacteriophage for treatment of some purulent processes. Cited by N. Chanishvili (2009) A literature review of the practical application of bacteriophages research. Eliava Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia.
29. Shevyakova O.L. Effect of phages on the antibiotic-resistant bacteria Dysenteriae flexneri. Antibiotics 1956, N6:40-42.
30. Shevyakova O.L., et al. Treatment of dysentery in children with polymyxin and bacteriophages. Antibiotics 1964, 3:269-272.
31. Kutter E., et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11:69-86.
32. Comeau A.M., et al. Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotic stimulate virulent phage growth. PLoS One 2007, 2:e799.
33. Merabishvili M., et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009, 4:e4944.
34. Wright A., et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report efficacy. Clin. Otolaryngol. 2009, 34:349-357.
35. Slopek S., et al. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. 1983, 31:267-291.
36. Slopek S., et al. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch. Immunol. Ther. Exp. 1983, 31:293-327.
37. Slopek S., et al. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch. Immunol. Ther. Exp. 1984, 32:317-335.
38. Babalova E.G., et al. Preventive value of dried dysentery bacteriophage. Zh. Mikrobiol. Epidemiol. Immunobiol. 1968, 2:143-145.